

DelRicht Achieves 276.7% of the Enrollment Goal in a Phase 3 Obesity Trial

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 3 obesity study targeting adults 18+ with obesity and at least one weight-related comorbidity (including hypertension, dyslipidemia, sleep apnea, or cardiovascular disease) and excluding T2DM.

- **Study Enrollment Goal:** 3,500 patients across 170 sites
- **DelRicht's Enrollment Goal:** 20 patients at 1 site
- **Patient Population:** Adults 18+ with obesity
- **Enrollment Period:** December 2025 – August 2026 (8 months)

Activation to Screening Timeline



The Study

Client: Large Biotech

Trial: U.S. Phase 3 Obesity Trial

Participating PI



Dr. Robert Springer
General Medicine
Atlanta, GA



Atlanta, GA
Springer Wellness & Restorative Health

Key Trial Challenges & Solutions

CHALLENGE

Long-Term Retention:

The combination of the extended 98-week **study duration and frequent site visit schedule** ultimately led to cumulative **patient fatigue**, creating a secondary layer of attrition that compounded burden driven by early **gastrointestinal side effects** and **placebo-arm discontinuation**.



HOW DELRICHT ADDRESSED

Strategic Engagement:

The site mitigated discontinuation through **proactive placebo and side effect education**, flexibly **accommodated scheduling** where possible to fit patient lifestyles, and highlighted **participation benefits** including ongoing lifestyle and nutritional guidance from trained medical professionals.

Our Results

DelRicht's site in Atlanta, GA successfully **enrolled 57 participants, 276.7% of the expected enrollment goal, with a 98.3% retention rate**. In addition, Dr. Springer's team was able to achieve a rapid **2-day activation to first patient first visit** timeline. This performance highlights the strength of our operational excellence and patient-centered approach to ensuring high-quality data in large scale obesity studies.



57 Participants Enrolled



276.7% of the Expected Enrollment Goal



98.3% Retention Rate